Voloridge Investment Management
ANIK icon

Voloridge Investment Management’s Anika Therapeutics ANIK Stock Holding History

Voloridge Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,309
Closed -$356K – 1241
2020
Q1 		$356K Sell
12,309
-20,470
-62% -$828K 0.01% 813
2019
Q4 		$1.7M Buy
32,779
+12,839
+64% +$746K 0.03% 525
2019
Q3 		$1.09M Buy
19,940
+13,330
+202% +$684K 0.02% 615
2019
Q2 		$268K Buy
+6,610
New +$241K 0.01% 662

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Voloridge Investment Management's ANIK Position: Q2 2020 in Review

Voloridge Investment Management sold out of Anika Therapeutics (ANIK) in Q2 2020, closing a stake of 12,309 shares — an estimated $356K sold.

Voloridge Investment Management first reported a position in ANIK in Q2 2019 and held it in 4 quarters. The position peaked at $1.7M in Q4 2019. 158 funds tracked by Wall St. Rank hold ANIK as of Q2 2020.

  • Voloridge Investment Management reported no remaining Anika Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Voloridge Investment Management sold 12,309 Anika Therapeutics shares in Q2 2020, an estimated $356K.
  • Voloridge Investment Management first reported a position in Anika Therapeutics in Q2 2019 and held it in 4 quarters.
  • Voloridge Investment Management's Anika Therapeutics position peaked at $1.7M in Q4 2019.
  • 158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2020.

Based on Voloridge Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.